Physician profile
Steven A Pollack
NPI 1477525806
$1,096.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $160 · 2021: $388 · 2022: $242 · 2023: $38.31 · 2024: $15.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $211.76 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $204.57 | 2019-2023 | |
| Pfizer INC. | $147.03 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $113.65 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $111.77 | 2020-2021 | |
| Heartflow, INC. | $57.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.67 | 2019-2022 | |
| Bardy Diagnostics, INC. | $25.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.78 | 2021 | |
| Esperion Therapeutics, INC. | $18.90 | 2020 | |
| Merck Sharp & Dohme LLC | $17.34 | 2021 | |
| Atricure, INC. | $17.15 | 2022 | |
| Bausch & Lomb Americas INC. | $15.51 | 2024 | Vyzulta |
| Medicure Pharma INC. | $14.28 | 2023 | Zypitamag |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.49 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.